574 related articles for article (PubMed ID: 11852819)
1. [The role of cyclooxygenase and prostaglandins in the pathogenesis of rheumatoid arthritis].
Stańczyk J; Kowalski ML
Pol Merkur Lekarski; 2001 Nov; 11(65):438-43. PubMed ID: 11852819
[TBL] [Abstract][Full Text] [Related]
2. Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells.
Yamazaki R; Kawai S; Matsumoto T; Matsuzaki T; Hashimoto S; Yokokura T; Okamoto R; Koshino T; Mizushima Y
J Pharmacol Exp Ther; 1999 May; 289(2):676-81. PubMed ID: 10215639
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes.
Vergne P; Liagre B; Bertin P; Cook-Moreau J; Treves R; Beneytout JL; Rigaud M
J Rheumatol; 1998 Mar; 25(3):433-40. PubMed ID: 9517759
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissue.
McEvoy AN; Bresnihan B; FitzGerald O; Murphy EP
Arthritis Rheum; 2004 Apr; 50(4):1132-45. PubMed ID: 15077295
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants.
Hardy MM; Seibert K; Manning PT; Currie MG; Woerner BM; Edwards D; Koki A; Tripp CS
Arthritis Rheum; 2002 Jul; 46(7):1789-803. PubMed ID: 12124863
[TBL] [Abstract][Full Text] [Related]
6. The unmet anti-inflammatory needs in orthopedics.
Trippel SB
Am J Orthop (Belle Mead NJ); 1999 Mar; 28(3 Suppl):3-7. PubMed ID: 10193996
[TBL] [Abstract][Full Text] [Related]
7. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
Kusunoki N; Yamazaki R; Kawai S
Arthritis Rheum; 2002 Dec; 46(12):3159-67. PubMed ID: 12483719
[TBL] [Abstract][Full Text] [Related]
8. Induction of cyclooxygenase-1 in cultured synovial cells isolated from rheumatoid arthritis patients.
Onodera M; Horiuchi Y; Nakahama K; Muneta T; Mano Y; Morita I
Inflamm Res; 2004 Jun; 53(6):217-22. PubMed ID: 15167967
[TBL] [Abstract][Full Text] [Related]
9. Defining COX-2 inhibitors.
Lipsky PE
J Rheumatol Suppl; 2000 Oct; 60():13-6. PubMed ID: 11032097
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of cyclooxygenase 2-generated prostaglandin E2 synthesis in rheumatoid arthritis synoviocytes by taurine chloramine.
Kontny E; Rudnicka W; Kowalczewski J; Marcinkiewicz J; Maslinski W
Arthritis Rheum; 2003 Jun; 48(6):1551-5. PubMed ID: 12794822
[TBL] [Abstract][Full Text] [Related]
11. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
12. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases.
Siegle I; Klein T; Backman JT; Saal JG; Nüsing RM; Fritz P
Arthritis Rheum; 1998 Jan; 41(1):122-9. PubMed ID: 9433877
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis.
Milas L
Am J Clin Oncol; 2003 Aug; 26(4):S66-9. PubMed ID: 12902859
[TBL] [Abstract][Full Text] [Related]
14. Cloning, expression, and selective inhibition of canine cyclooxygenase-1 and cyclooxygenase-2.
Gierse JK; Staten NR; Casperson GF; Koboldt CM; Trigg JS; Reitz BA; Pierce JL; Seibert K
Vet Ther; 2002; 3(3):270-80. PubMed ID: 12447834
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors.
van der Bijl P; van der Bijl P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700
[TBL] [Abstract][Full Text] [Related]
16. COX-1 and COX-2 in health and disease.
Adelizzi RA
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S7-12. PubMed ID: 10643175
[TBL] [Abstract][Full Text] [Related]
17. Safety of anti-inflammatory treatment--new ways of thinking.
Brune K
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i16-20. PubMed ID: 14752171
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.
Kurumbail RG; Stevens AM; Gierse JK; McDonald JJ; Stegeman RA; Pak JY; Gildehaus D; Miyashiro JM; Penning TD; Seibert K; Isakson PC; Stallings WC
Nature; 1996 Dec 19-26; 384(6610):644-8. PubMed ID: 8967954
[TBL] [Abstract][Full Text] [Related]
19. Induction of COX-2 expression by nitric oxide in rheumatoid synovial cells.
Honda S; Migita K; Hirai Y; Ueki Y; Yamasaki S; Urayama S; Kawabe Y; Fukuda T; Kawakami A; Kamachi M; Kita M; Ida H; Aoyagi T; Eguchi K
Biochem Biophys Res Commun; 2000 Feb; 268(3):928-31. PubMed ID: 10679307
[TBL] [Abstract][Full Text] [Related]
20. COX inhibitors and their effects on bone healing.
Gerstenfeld LC; Einhorn TA
Expert Opin Drug Saf; 2004 Mar; 3(2):131-6. PubMed ID: 15006719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
